Objective: Duplex ultrasound (DUS) surveillance of infrainguinal vein bypass grafts is widely practiced, but the evidence of its effectiveness compared with other methods of surveillance remains unclear.
Autogenous vein is the preferred conduit for open surgical reconstructions in the lower extremity that require bypass grafts. 1 However, when placed in the arterial system, vein grafts can develop stenotic lesions that lead to graft thrombosis and recurrent symptoms of lower extremity ischemia. 2, 3 Such lesions have been observed in 30% to 50% of vein grafts observed for up to 5 years. 2 Serial follow-up or surveillance of infrainguinal vein bypass grafts by some combination of clinical assessment, measurement of ankle-brachial index (ABI), and duplex ultrasound (DUS) scanning has been recommended to identify lesions that threaten graft patency and to facilitate selective repeated interventions to maintain graft function. Surveillance protocols have resulted in primary, assisted primary, and secondary patency rates of 61%, 77%, and 80%, respectively, at 1 year. 2 Although the number of vein bypass grafts has decreased in recent years as the use of endovascular interventions has increased, vein grafts continue to be performed in relatively large numbers. 4 Surveillance of infrainguinal vein grafts by DUS has been strongly advocated and widely practiced; however, the clinical evidence supporting this approach has been conflicting, and the best method to monitor the patency and to optimize outcomes of these grafts remains unclear. [5] [6] [7] To support the development of clinical practice guidelines by the Society for Vascular Surgery, we conducted a systematic review and meta-analysis to synthesize the existing evidence about the effectiveness of DUS surveillance for infrainguinal vein bypass grafts.
METHODS
This systematic review followed a protocol that was developed a priori by a panel of experts from the Society for Vascular Surgery who were tasked with developing a guideline on the topic. The reporting of this review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 8 Study eligibility. We included randomized or nonrandomized comparative studies. The search was not limited by language, sample size, or date of publications. We searched for studies that included patients who had received autologous vein grafts for lower extremity arterial reconstruction (bypass surgery) not including the aorta (ie, in the femoral or infrainguinal region) who afterward received DUS surveillance for follow-up compared with any other method of surveillance. There was no minimal follow-up period. Abstracts and titles that resulted from executing the search strategy were independently evaluated by two reviewers from this review study team for potential eligibility, and the full-text versions of all potentially eligible studies were obtained. Reviewers working in duplicate and independently considered the full-text reports for eligibility. Disagreements were harmonized by consensus and through arbitration by a third reviewer if consensus was not possible.
Literature search. The search included the electronic databases MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, Cumulative Index to Nursing and Allied Health Literature, and Scopus (Appendix, online only). We expanded the search to include all languages, with latest date of inclusion to be November 2016. We also cross-referenced with previously published literature and included what was deemed eligible.
Data extraction. Using a standardized form, two reviewers independently extracted data from each study and later reconciled differences, if present. Reviewers independently determined the methodologic quality of studies and collected descriptive and outcome data. Reviewers extracted data on patient demographics and baseline characteristics, interventions compared with DUS, study design variables, sample size, length of follow-up, number of patients in each intervention, and outcomes of interest and clinically pertinent variables (eg, presence of comorbidities, indication for surgery, vessels repaired, type of vein graft used, graft anatomic location, peak systolic velocity index).
Risk of bias assessment and quality of evidence. We used the Cochrane Collaboration risk of bias assessment tool for randomized trials, focusing on randomization methods, allocation concealment, blinding, and attrition. 9 We used the Newcastle-Ottawa Scale 10 for cohort and case-control studies; for uncontrolled studies, we used the quality assessment tool for case series studies ascertained by the National Institutes of Health. 11 We graded the strength of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach.
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Outcomes definition. We included studies that reported any outcomes of interest: all-cause mortality; cardiovascular mortality; limb viability; functional status; quality of life; daily activities scores; and graft patency reports, such as primary patency, assisted primary patency, and secondary patency. A revised vein referred to a vein bypass graft that had undergone a local procedure to maintain patency, such as vein patch angioplasty, replacement of a short segment, or balloon angioplasty. However, this would not apply if the entire original vein graft was replaced by a new graft, in which case it would be considered a new vein graft. For postoperative graft occlusion, we extracted data from studies reporting any graft that became totally occluded (ie, no flow at all) at some time after it was placed. For postoperative graft stenosis, this referred to a graft that developed a narrowing at some time after it was placed but remained patent (ie, not completely occluded but may not be adequate for normal function). Primary patency ascertained the time interval beginning with the original operation during which a graft remains continuously patent without any interventions to maintain patency. The period of primary patency ends if an intervention is done to maintain patency or if the graft occludes. Assisted primary patency begins at the time of the original operation and refers to continuous patency but includes periods of patency after interventions intended to maintain patency. A period of assisted primary patency ends if the graft occludes. Secondary patency was defined by when a graft occludes but then has patency restored by some type of intervention (ie, secondary patency includes the period of primary or assisted primary patency plus any additional period of patency after intervention for graft occlusion). All-cause mortality was ascertained by death due to any reason; major amputation was defined as above-ankle amputations.
Statistical analysis. We extracted or calculated the rate of outcomes of interest along with the confidence interval estimated by the Jeffreys method. 13 Rates were combined using the DerSimonian and Laird randomeffects methods after log transforming the rates. 14 For binary outcomes, odds ratio under 1.0 suggests lower risk associated with surveillance. The I 2 static was used to assess heterogeneity of the treatment effect among studies for each outcome. I 2 value >50% and P < .10 of the Cochrane Q test suggest substantial heterogeneity that is due to real differences in study populations, protocols, interventions, or outcomes. Visual inspection of funnel plots and the Egger linear regression tests were planned to evaluate potential publication bias. 15 All statistical analyses were performed using Stata version 12 (StataCorp LP, College Station, Tex).
RESULTS
The initial search resulted in 455 publications. After reviewing the abstracts, we limited the number of potentially relevant publications to 123 articles. Two more publications were identified through reference review of the selected articles. These 125 articles were reviewed in full text by two reviewers. Eventually, 15 studies were included 5, 6, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] ; 110 articles were excluded for the reasons shown in Supplementary Fig 1 (online  only) . The baseline characteristics of participants of included studies are summarized in Supplementary  Table I (online only). All studies included autologous grafts. One study 18 reported outcomes of interest in a mixed population (ie, autologous and synthetic grafts), and therefore it was deemed not eligible and excluded from the final analysis. A second study included mixed graft types but provided data for autologous grafts separately, and hence that subgroup was included. 6 Five studies were clinical trials, eight were case series, one was a case-control study, and one was a cohort study. Supplementary Table II , A-C (online only), shows the risk of bias assessment. The corresponding surveillance interventions used and number of patients in each study are shown in Table I . Results of each study and those of the meta-analysis are shown in Tables II  and III, respectively. There was a variation in the DUS surveillance protocols in the included studies as shown in Supplementary Table I (online only) . Among the identified studies, four studies used clinical followup with arteriography as a method of surveillance compared with DUS, whereas nine studies used a combination of clinical follow-up with ABI to compare. Two studies compared three surveillance interventions (ie, DUS vs arteriography vs ABI and clinical follow-up). Publication bias was not possible to ascertain because of an insufficient number of studies per outcome reported. Meta-analysis. Compared with ABI coupled with clinical examination, DUS surveillance was not associated with a significant change in primary, secondary, or assisted primary patency or mortality (Table II ; Figs 1-3; Supplementary Fig 2, online only) . DUS surveillance was associated with a nonsignificant reduction in amputation rate (odds ratio, 0.70; confidence interval, 0.23-2.13; Supplementary Fig 3, online only) . All other outcomes of interest did not show any significant difference (Supplementary Figs 3-7 , online only). One study 16 compared DUS of infrainguinal vein bypasses with intra-arterial digital subtraction angiography as the "gold standard" to determine the severity of the stenosis. The diameter reduction measured by color flow imaging was best to identify all stenotic lesions >29% (sensitivity, 88%; specificity, 99%). Peak systolic velocity index provided optimal identification of stenoses >49% (sensitivity, 89%; specificity, 92%), and 70% to 99% stenoses were associated with increased end-diastolic velocity (sensitivity, 91%; specificity, 100%). This study supports the value of surveillance of femorodistal vein grafts and demonstrates that calculation of the degree of graft stenosis is feasible. Another study compared DUS with computed tomography angiography (CTA) for detection of stenoses in vein grafts. 30 Whereas certain DUS velocity parameters were strongly correlated with vein graft failure, there was a poor correlation between high-grade stenosis on CTA and vein graft failure. The lack of a direct correlation between DUS and CTA in this study was most likely due to the fundamental differences between these two imaging methods, with DUS assessing flow dynamics and CTA based primarily on anatomic features. A priori established subgroup analyses (follow-up length and study design [interventional trials vs observational studies]) did not show a statistically significant difference. Other a priori clinically relevant subgroup analyses, including by type and origin of vein graft, type of occlusion site, lesion classification, presence of diabetes and other comorbidities, type of surveillance protocol, and cost-effectiveness, were not possible because of inconsistent or insufficient reporting. The quality of evidence (confidence in evidence) was lowered because of increased risk of bias, imprecision, and heterogeneity.
DISCUSSION
In this systematic review and meta-analysis, low-quality evidence suggests that the use of DUS surveillance for infrainguinal vein bypass grafts was not associated with statistically significant changes in clinical outcomes. The quality of the available evidence was low (ie, the certainty of these estimates is low, and future research will likely produce substantially different estimates). 31 
DUS
scanningdwhen it is used with appropriate velocity and image criteriadcan identify lesions that threaten graft patency at an early stage, when they can be repaired by relatively simple interventions, thus avoiding graft occlusion. Patients who do not receive surveillance would be deprived of early interventions, which may provide a rationale for surveillance. Data on patient-important outcomes, such as mortality and amputation risk, are currently limited. The report of the Inter-Society Consensus for the Management of Peripheral Arterial Disease recommended a clinical surveillance program consisting of interval history, vascular physical examination, and measurement of ABI without routine DUS scanning. 32 However, in spite of this lack of high-quality evidence, a number of singlecenter studies have identified DUS velocity parameters that appear to be predictive of vein graft thrombosis. 30, 33 It has been suggested that patients with these "higher risk" bypass grafts may benefit from either intervention to prevent thrombosis or a more a more rigorous surveillance protocol. 7 Recognizing the severe consequences of lower extremity vein graft failure and the challenge of restoring patency once thrombosis has occurred, many vascular surgeons have elected to use some form of DUS surveillance in their patients. The rationale for this approach is also based on the noninvasive nature and relatively low cost of a DUS surveillance program compared with other imaging modalities. In a report on performance measures for adults with peripheral artery disease from a multidisciplinary writing panel, routine surveillance with DUS was recommended after femoral-popliteal and femoral-tibial-pedal vein bypass grafts with surveillance intervals of approximately 3, 6, and 12 months and then yearly thereafter. 34 Another multidisciplinary report described "appropriate use criteria" for arterial ultrasound and physiologic testing. 35 Surveillance with DUS scanning and ABI was considered "appropriate" after a lower extremity vein bypass graft as a postoperative baseline (within 1 month), at intervals of 6 to 8 months during the first year, and at 12-month intervals thereafter in a patient who remained asymptomatic or had stable symptoms. The limitations of this systematic review relate to the sparse randomized evidence. Some of the included studies were older; however, the basic approach to DUS surveillance of vein grafts has not changed substantially since it was described in the 1990s.
CONCLUSIONS
A recommendation for routine DUS surveillance of infrainguinal vein grafts remains dependent on lowquality evidence. Considering that DUS offers the opportunity of early intervention and because of its noninvasive nature and low cost, vascular surgeons may incorporate DUS as they individualize the follow-up of lower extremity vein grafts. Follow-up approach can be based on patient factors and preferences, physiologic tests, and imaging modalities that they consider most likely to identify grafts at risk for failure and in need of repeated intervention. 
AUTHOR CONTRIBUTIONS

